Publikationen in Zusammenarbeit mit Forschern von Dana–Farber Cancer Institute (74)

2024

  1. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis from the Randomized Phase II ELOQUENT-3 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 568-578

  2. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria

    Seminars in Hematology

  3. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

    Seminars in Hematology

2022

  1. Genomic profiling for clinical decision making in lymphoid neoplasms

    Blood

  2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Idecabtagene Vicleucel in Relapsed Myeloma. Reply

    The New England journal of medicine

  2. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

  3. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

  2. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2019

  1. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

    European Journal of Haematology, Vol. 102, Núm. 6, pp. 494-503

  2. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

    British Journal of Haematology

2018

  1. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    New England Journal of Medicine, Vol. 379, Núm. 19, pp. 1811-1822

  2. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

    Blood Cancer Journal, Vol. 8, Núm. 11

2017

  1. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

    British Journal of Haematology, Vol. 178, Núm. 4, pp. 547-560

  2. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

    European Journal of Haematology, Vol. 99, Núm. 3, pp. 199-206

  3. Deacetylase inhibitors: an advance in myeloma therapy?

    Expert Review of Hematology, Vol. 10, Núm. 3, pp. 229-237

  4. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905

  5. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

    Blood, Vol. 130, Núm. 24, pp. 2610-2618